Physician profile
Thomas Stone
NPI 1528064219
$79,432.93
in general payments reported to CMS, 2019-2025
33 companies · $16K in 2025
The $16K reported for 2025 was more than what 93% of Retina Specialist providers received nationally (typical 2025 total: $460).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $12K · 2020: $1,092 · 2021: $6,997 · 2022: $13K · 2023: $15K · 2024: $16K · 2025: $16K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $32K · Food and Beverage: $8,317 · Honoraria: $4,815 · Travel and Lodging: $627.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $32,330.00 |
| Food and Beverage | $8,317.05 |
| Honoraria | $4,815.00 |
| Travel and Lodging | $626.58 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Regeneron Healthcare Solutions, INC. | $24,269.61 | 2019-2025 | Eylea Hd, Eylea |
| Genentech USA, INC. | $10,932.87 | 2019-2025 | Vabysmo, Susvimo |
| Alcon Vision LLC | $8,424.49 | 2019-2025 | Unity, Ngenuity, Constellation |
| Alimera Sciences, INC. | $6,819.01 | 2019-2024 | Iluvien, Yutiq |
| Regeneron Pharmaceuticals, INC. | $5,783.44 | 2021-2023 | Eylea |
| Carl Zeiss Meditec, INC. | $4,021.73 | 2019 | |
| Harrow Eye, LLC | $3,727.75 | 2024-2025 | Triesence, Iheezo |
| Alcon Research LLC | $3,161.92 | 2022-2025 | |
| Ocular Therapeutix, INC. | $2,342.61 | 2022-2023 | |
| Genentech, INC. | $1,882.38 | 2021-2022 | |
| Ani Pharmaceuticals, INC. | $1,735.61 | 2024-2025 | Iluvien, Purified Cortrophin Gel, Yutiq |
| Optos, INC. | $1,033.72 | 2020-2022 | |
| Astellas Pharma US INC | $994.90 | 2023-2025 | Izervay |
| Apellis Pharmaceuticals, INC. | $960.96 | 2022-2025 | Syfovre |
| Abbvie INC. | $544.41 | 2023-2025 | Ozurdex |
Show all 33 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $475.54 | 2019-2021 | |
| Allergan, INC. | $421.68 | 2019-2022 | |
| Eyepoint US, INC. | $392.61 | 2019-2024 | |
| Dutch Ophthalmic, USA | $250.58 | 2025 | Tissueblue, Eva, Combined Machine |
| Biogen, INC. | $217.21 | 2022-2024 | Byooviz |
| Amgen INC. | $136.66 | 2024-2025 | Pavblu, Lumakras |
| Kala Pharmaceuticals, INC. | $135.51 | 2019 | |
| New World Medical,INC. | $131.25 | 2023 | |
| Horizon Therapeutics Plc | $124.74 | 2021 | |
| Aerie Pharmaceuticals, INC. | $122.47 | 2019 | |
| Neurotech Pharmaceuticals, INC. | $117.60 | 2025 | |
| Johnson & Johnson Surgical Vision, INC. | $107.76 | 2023 | Tecnis Iol |
| Mallinckrodt Hospital Products INC. | $65.57 | 2021 | |
| Coherus Oncology, INC. | $27.14 | 2023 | |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $24.42 | 2020 | |
| Bausch & Lomb Americas INC. | $19.98 | 2022 | |
| Spark Therapeutics, INC. | $13.42 | 2019 | |
| Notal Vision, INC. | $13.38 | 2024 | Foresee Home |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Thomas Stone listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.